Redelmeier Donald, Scales Damon, Kopp Alexander
Sunnybrook and Women's College Health Sciences Centre, G-151, 2075 Bayview Ave, Ontario, Canada M4N 3M5.
BMJ. 2005 Oct 22;331(7522):932. doi: 10.1136/bmj.38603.746944.3A. Epub 2005 Oct 6.
To test whether atenolol (a long acting beta blocker) and metoprolol (a short acting beta blocker) are associated with equivalent reductions in risk for elderly patients undergoing elective surgery.
Population based, retrospective cohort analysis.
Acute care hospitals in Ontario, Canada, over one decade.
Consecutive patients older than 65 who were admitted for elective surgery, without symptomatic coronary disease.
Death or myocardial infarction.
37,151 patients were receiving atenolol or metoprolol before surgery, of which the most common operations were orthopaedic or abdominal procedures. As expected, the two groups were similar in demographic characteristics, medical therapy, and type of surgery. 1038 patients experienced a myocardial infarction or died, a rate that was significantly lower for patients receiving atenolol than for those receiving metoprolol (2.5% v 3.2%, P < 0.001). The decreased risk with atenolol persisted after adjustment for measured demographic, medical, and surgical factors; extended to comparisons of other long acting and short acting beta blockers; was accentuated in analyses that focused on patients with the clearest evidence of beta blocker treatment; and reflected the immediate postoperative interval.
Patients receiving metoprolol do not have as low a perioperative cardiac risk as patients receiving atenolol, in accord with possible acute withdrawal after missed doses.
测试阿替洛尔(一种长效β受体阻滞剂)和美托洛尔(一种短效β受体阻滞剂)对于接受择期手术的老年患者,在降低风险方面是否具有等同效果。
基于人群的回顾性队列分析。
加拿大安大略省的急症医院,时间跨度超过十年。
连续入选的65岁以上因择期手术入院且无冠心病症状的患者。
死亡或心肌梗死。
37151例患者在手术前接受阿替洛尔或美托洛尔治疗为,其中最常见的手术是骨科手术或腹部手术。正如预期的那样,两组在人口统计学特征、药物治疗和手术类型方面相似。1038例患者发生心肌梗死或死亡,接受阿替洛尔治疗的患者发生率显著低于接受美托洛尔治疗的患者(2.5%对3.2%,P<0.001)。在对测量的人口统计学、医学和手术因素进行调整后,阿替洛尔降低风险的效果依然存在;扩展到其他长效和短效β受体阻滞剂的比较中;在针对有最明确β受体阻滞剂治疗证据的患者的分析中更为明显;并且反映在术后即刻时间段。
与接受阿替洛尔治疗的患者相比,接受美托洛尔治疗的患者围手术期心脏风险没有那么低,这与漏服药物后可能出现的急性撤药反应一致。